Primaquine Enantiomers in G6PD Deficient Human Volunteers
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study is a single center, prospective, cross-over phase 1 trial. Eighteen subjects will
be enrolled in the study evaluating the metabolism, pharmacokinetic behavior and tolerability
of primaquine enantiomers and placebo over the course of 5 days.
Phase:
Phase 1
Details
Lead Sponsor:
University of Mississippi, Oxford
Collaborators:
Southern Research Southern Research Institute University of Colorado, Denver